Skip to main content
SVBI logo

SVBI — Investor Relations & Filings

Ticker · 1786 ISIN · TW0001786002 TW Manufacturing
Open in API
Filings indexed 1,687 across all filing types
Latest filing 2023-08-11 Regulatory Filings
Country TW Taiwan
Listing TW 1786

About SVBI

www.scivision.com.tw

SciVision Biotech Inc. is a specialized developer and manufacturer of advanced medical devices, focusing on the research and production of hyaluronic acid (HA) products. The company leverages its proprietary Crosslinked Hyaluronic Acid Platform (CHAP) technology to create high-performance solutions across multiple medical disciplines. Its core product portfolio includes subcutaneous fillers for facial aesthetics, intra-articular injections for orthopedic joint care, anti-adhesion gels for surgical applications, and vesical instillation solutions for urological treatments. By integrating specialized R&D capabilities with precision manufacturing, SciVision Biotech provides medical-grade HA applications designed to improve patient outcomes in aesthetics and therapeutic recovery. The company is committed to scientific innovation and the expansion of its patented technology to meet diverse clinical needs in the global healthcare market.

Recent filings

Filing Released Lang Actions
112年第2季大陸投資
Regulatory Filings Classification · 90% confidence The document is a detailed tabular disclosure of investment amounts and related financial data concerning investments in mainland China by a Taiwanese listed company. It includes specific financial figures, investment methods, and regulatory limits as per the Ministry of Economic Affairs Investment Commission. The document is relatively short (1288 characters) and contains substantive financial data related to investments, not just an announcement or a certification. It does not resemble an annual or quarterly report, audit report, or earnings release. Instead, it fits the profile of a Regulatory Filing (RNS) because it is a regulatory disclosure of investment information required by authorities, but it does not match any other more specific category such as capital update or major shareholding notification. Therefore, the best classification is Regulatory Filings (RNS).
2023-08-11 Chinese
公告本公司公司治理主管異動
Board/Management Information Classification · 100% confidence The document is a short announcement (707 characters) about a change in the company's governance personnel, specifically the company governance supervisor. It details the old and new persons in the role, the date of change, and the nature of the change (position adjustment). There is no financial data, no report attached or referenced, and it clearly relates to management changes. According to the definitions, this fits the category 'Board/Management Information (MANG)' which covers announcements of changes in the company's board or senior management.
2023-08-10 Chinese
公告本公司國內第二次無擔保轉換公司債第二季 轉換普通股之發行新股基準日
Share Issue/Capital Change Classification · 100% confidence The document is a company announcement regarding the issuance of new shares due to the conversion of domestic unsecured convertible bonds. It includes details such as the board resolution date, amount and number of shares issued, capital increase, and related procedural information. There is no financial statement or comprehensive report content, but rather a specific update on capital structure changes. This fits the definition of a Share Issue/Capital Change announcement (SHA). The document length is short and focused on capital issuance details, not a full financial report or other category.
2023-08-10 Chinese
112年08月法人說明會簡報 — 178620230810E001.pdf
Investor Presentation Classification · 95% confidence The document is titled 'Investor Conference 2023' and contains detailed information about the company's products, technology, market insights, and business operations. It includes forward-looking statements, product descriptions, market data, and scientific references. There is no indication that this is a formal financial report such as an Annual Report (10-K) or Interim Report (IR). It is not a transcript of a call, nor an announcement of voting results or capital changes. The content is consistent with a presentation aimed at investors, focusing on business strategy, product portfolio, and market positioning. The length (15,000 characters) and detailed content support that this is a full presentation document rather than a brief announcement or regulatory filing. Therefore, the most appropriate classification is Investor Presentation (IP).
2023-08-10 Chinese
112年08月法人說明會簡報 — 178620230810M001.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a detailed presentation from SciVision Biotech Inc. for the year 112 (Taiwan calendar year, corresponding to 2023). It includes extensive information about the company, its products, market insights, scientific references, and detailed financial data such as consolidated income statements, balance sheets, and cash flow statements for the first half of 2023 and 2022. The presence of comprehensive financial statements and operational data for a half-year period indicates this is an Interim / Quarterly Report. The document length (15,000 characters) and the inclusion of substantive financial data confirm it is not merely an announcement or a presentation but a full financial report for a period shorter than a fiscal year. Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2023
2023-08-10 Chinese
112年08月法人說明會簡報
Investor Presentation Classification · 95% confidence The document is a listing from a public information observation station showing details about a scheduled investor conference call or presentation (法人說明會 translates to 'investor conference' or 'analyst meeting'). It includes company code, name, date, time, location (online), summary of the meeting, links to presentation files (PDFs), and video links. There is no financial data or report content itself, only references to presentation materials and meeting details. This matches the definition of an Investor Presentation (IP) filing, which is a detailed presentation for investors focusing on financials, strategy, and market position. The document length is short and it is not an announcement of a report publication but the actual presentation materials and meeting info. Therefore, the correct classification is Investor Presentation (IP).
2023-08-10 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.